18 completed, 3 unknown, 1 active not recruiting, 1 not yet recruiting. 24 Phase 2, 4 Phase 1, 4 Phase 3.
Follow Pertussis: new trials by email Literature Review of Pertussis trials Research Report on Pertussis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine low-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), high-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), Tetanus, Diphtheria and Acellular Pertussis Vaccine - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus | Phase 1 / Phase 2 | Not yet recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 660 | 2026-03-12 | 2026-02-18 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp)), 23-valent Pneumococcal Polysaccharide Vaccine (PPV23), Tdcp - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | CanSino Biologics Inc. | 1820 | 2024-12-20 | 2026-08-26 |
| Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2024-10-02 | 2024-10-01 |
| Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines Pertagen®, Revaxis® - Pertussis, Vaccine-Preventable Diseases | Phase 2 / Phase 3 | Unknown | University Hospital, Geneva | 100 | 2022-02-07 | 2022-01-18 |
| Maternal Pertussis Wholecell Responses Standard of care vaccines, Boostagen, (BioNet-Asia) - Pertussis | Phase 2 | Completed | St George's, University of London | 181 | 2020-10-21 | 2023-11-22 |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2019-11-01 | 2019-09-06 |
| Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device - Pertussis, Whooping Cough | Phase 2 | Completed | ILiAD Biotechnologies | 300 | 2019-06-15 | 2023-06-27 |
| Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants Tetanus and Diphtheria Toxoids Adsorbed, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide - Clostridium Difficile Immunisation, Diphtheria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 399 | 2019-01-24 | 2025-05-21 |
| Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults BPZE1, Placebo - Pertussis, Pertussis Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2018-10-23 | 2024-09-19 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
| The PertADO Geneva Trial Pertagen® aP + Td-pur®, Boostrix® dTpa - Pertussis | Phase 2 | Completed | Siegrist Claire-Anne | 60 | 2016-10-27 | 2017-05-08 |
| Maternal Tdap Immunization in Guatemala Tdap, Td - Pertussis, Whooping Cough | Phase 2 | Completed | Emory University | 286 | 2016-07-01 | 2019-10-16 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3 - Tetanus, Diphtheria | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1363 | 2015-10-22 | 2022-03-23 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents (ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis - Pertussis, Tetanus | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 43 | 2012-09-01 | 2014-02-21 |
| Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningococcal Meningitis, Tetanus | Phase 2 | Completed | Sanofi | 882 | 2006-10-01 | 2011-08-24 |
| Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar® Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC - Diphtheria, Pertussis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 460 | 2006-08-01 | 2014-01-14 |
| Pentavalent DTaP-Hep B-IPV DTaP-Hep B-IPV Vaccine, Monovalent Hep B Vaccine, Placebo - Diphtheria, Hepatitis B | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 2005-12-01 | 2011-11-07 |
| Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib - Hib Disease, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 175 | 2005-01-01 | 2017-05-30 |
Showing 20 of 24. Sign in to see all of them.
Whooping Cough (24) · Tetanus (18) · Diphtheria (17) · Hepatitis B (11) · Poliomyelitis (11) · Haemophilus Infections (7) · Bordetella Infections (1) · Gram-Negative Bacterial Infections (1) · Infections (1) · Meningitis, Meningococcal (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Vaccine-Preventable Diseases (1)
Bacterial Infections (24) · Bacterial Infections and Mycoses (24) · Bordetella Infections (23) · Gram-Negative Bacterial Infections (23) · Infections (23) · Respiratory Tract Diseases (23) · Respiratory Tract Infections (23) · Clostridium Infections (18) · Gram-Positive Bacterial Infections (18) · Actinomycetales Infections (17) · Corynebacterium Infections (17) · Virus Diseases (13) · Blood-Borne Infections (11) · Central Nervous System Diseases (11) · Central Nervous System Infections (11)
Tetanus Toxoid (7) · Vaccines, Combined (4) · Diphtheria-Tetanus-acellular Pertussis Vaccines (3) · Poliovirus Vaccine, Inactivated (3) · Hepatitis B Vaccines (2) · adacel (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Boostrix (1) · DTaP-IPV-HB-PRP-T vaccine (1) · FHD (1) · Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate (1) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (1) · Meningococcal Vaccines (1) · Pentavac (1) · Recombivax HB (1)
Sanofi Pasteur, a Sanofi Company (5) · LG Chem (4) · GlaxoSmithKline (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Institute of Medical Biology, Chinese Academy of Medical Sciences (2) · CanSino Biologics Inc. (1) · Emory University (1) · ILiAD Biotechnologies (1) · Sanofi (1) · Siegrist Claire-Anne (1) · St George's, University of London (1) · University Hospital, Geneva (1)
United States (6) · China (3) · Philippines (3) · Canada (2) · Switzerland (2) · Argentina (1) · Guatemala (1) · Japan (1) · Mali (1) · South Korea (1) · Uganda (1)
Barbara Rizzardi, MD (1) · Claire-Anne Siegrist, MD (1) · Edison Alberto, MD (1) · Hanqing He (1) · Jiawei Xu (1) · Josefina Carlos, MD (1) · Kirsty Le Doare, MBBS, PhD (1) · Manish Sadarangani, MRCPCH, DPHIL, BM.BCh, MA (1) · Mary B Manning, MD (1) · Saad B. Omer, MBBS,MPH,PhD (1)
PMID 20657177, PMID 21372751, PMID 23241989, PMID 24346596, PMID 25540274, PMID 30759183, PMID 36906345, PMID 38586589, PMID 39706666